Adjunctive intracoronary antithrombotic therapy: Time to revisit an old strategy

Journal of Invasive Cardiology

Volumn 21, Issue 5, 2009, Pages 224-228

  Srinivasan, Manivannan ^a   Prasad, Abhiram ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; CALCIUM; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; OXYGEN RADICAL; STREPTOKINASE; TIROFIBAN; UROKINASE;

ACUTE CORONARY SYNDROME; ANGIOCARDIOGRAPHY; BLEEDING; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY ARTERY THROMBOSIS; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; ENDOTHELIAL DYSFUNCTION; HEART INFARCTION; HEART MUSCLE CELL; HUMAN; MICROANGIOPATHY; RANDOMIZED CONTROLLED TRIAL; REVIEW; ST SEGMENT ELEVATION; STENT; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSTABLE ANGINA PECTORIS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; COMBINED MODALITY THERAPY; CORONARY THROMBOSIS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; STENTS; STREPTOKINASE; THROMBOLYTIC THERAPY;

EID: 67649596030     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Sherman C T, Litvack F, Grundfest W, et al. Coronary angioscopy in patients with unstable angina pectoris. N Engl J Med 1986;315:913-919.
2. DeWood MA, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980;303:897-902.
3. Kaul S, Ito H. Microvasculature in acute myocardial ischemia: Part I: Evolving concepts in pathophysiology, diagnosis, and treatment. Circulation 2004;109:146-149.
4. Kaul S, Ito H. Microvasculature in acute myocardial ischemia: Part II: Evolving concepts in pathophysiology, diagnosis, and treatment. Circulation 2004;109:310-315.
5. Beygui F, Collet J P, Nagaswami C, et al. Images in cardiovascular medicine. Architecture of intracoronary thrombi in ST-elevation acute myocardial infarction: Time makes the difference. Circulation 2006;113:e21-e23.
6. Davies MJ, Thomas AC, Knapman PA, Hangartner JR. Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death. Circulation 1986;73:418-427.
7. Henriques J P, Zijlstra F, Ottervanger J P, et al. Incidence and clinical significance of distal embolization during primary angioplasty for acute myocardial infarction. Eur Heart J 2002;23:1112-1117.
8. Saber RS, Edwards WD, Bailey KR, et al. Coronary embolization after balloon angioplasty or thrombolytic therapy: An autopsy study of 32 cases. J Am Coll Cardiol 1993;22:1283-1288.
9. Ito H, Okamura A, Iwakura K, et al. Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction. Circulation 1996;93:1993-1999.
10. Prasad A, Gersh BJ. Management of microvascular dysfunction and reperfusion injury. Heart 2005;91:1530-1532.
11. Bolognese L, Ducci K, Angioli P, et al. Elevations in troponin I after percutaneous coronary interventions are associated with abnormal tissue-level perfusion in high-risk patients with non-ST-segment-elevation acute coronary syndromes. Circulation 2004;110:1592-1597.
12. Prasad A, Stone GW, Stuckey TD, et al. Impact of diabetes mellitus on myocardial perfusion after primary angioplasty in patients with acute myocardial infarction. J Am Coll Cardiol 2005;45:508-514.
13. Prasad A, Stone G W, Aymong E, et al. Impact of ST-segment resolution after primary angioplasty on outcomes after myocardial infarction in elderly patients: An analysis from the CADILLAC trial. Am Heart J 2004;147:669-675.
14. Morishima I, Sone T, Okumura K, et al. Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol 2000;36:1202-1209.
15. Violaris AG, Melkert R, Herrman J P, Serruys P W. Role of angiographically identifiable thrombus on long-term luminal renarrowing after coronary angioplasty: A quantitative angiographic analysis. Circulation 1996;93:889-897.
16. Waxman S, Sassower MA, Mittleman MA, et al. Angioscopic predictors of early adverse outcome after coronary angioplasty in patients with unstable angina and non-Q-wave myocardial infarction. Circulation 1996;93:2106-2113.
17. Singh M, Berger PB, Ting HH, et al. Influence of coronary thrombus on outcome of percutaneous coronary angioplasty in the current era (the Mayo Clinic experience). Am J Cardiol 2001;88:1091-1096.
18. Muhlestein JB, Karagounis LA, Treehan S, Anderson JL. "Rescue" utilization of abciximab for the dissolution of coronary thrombus developing as a complication of coronary angioplasty. J Am Coll Cardiol 1997;30:1729-1734.
19. van den Brand M, Laarman GJ, Steg PG, et al. Assessment of coronary angiograms prior to and after treatment with abciximab, and the outcome of angioplasty in refractory unstable angina patients. Angiographic results from the CAPTURE trial. Eur Heart J 1999;20:1572-1578.
20. Karvouni E, Katritsis DG, Ioannidis J P. Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions. J Am Coll Cardiol 2003;41:26-32.
21. Montalescot G, Antoniucci D, Kastrati A, et al. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: A European meta-analysis on individual patients' data with long-term follow-up. Eur Heart J 2007;28:443-449.
22. Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002;346:957-966.
23. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-1903.
24. Neumann FJ, Blasini R, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation 1998;98:2695-2701.
25. Grines CL, Cox DA, Stone GW, et al. Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 1999;341:1949-1956.
26. Sianos G, Papafaklis MI, Daemen J, et al. Angiographic stent thrombosis after routine use of drug-eluting stents in ST-segment elevation myocardial infarction: The importance of thrombus burden. J Am Coll Cardiol 2007;50:573-583.
27. Vlaar PJ, Svilaas T, van der Horst IC, et al. Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS): A 1-year follow-up study. Lancet 2008;371:1915-1920.
28. Svilaas T, Vlaar PJ, van der Horst IC, et al. Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med 2008;358:557-567.
29. Burzotta F, Testa L, Giannico F, et al. Adjunctive devices in primary or rescue PCI: A meta-analysis of randomized trials. Int J Cardiol 2008;123:313-321.
30. De Luca G, Suryapranata H, Stone G W, et al. Adjunctive mechanical devices to prevent distal embolization in patients undergoing mechanical revascularization for acute my-ocardial infarction: A meta-analysis of randomized trials. Am Heart J 2007;153:343-353.
31. Wohrle J, Grebe OC, Nusser T, et al. Reduction of major adverse cardiac events with in-tracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty. Circulation 2003;107:1840-1843.
32. Gibson CM, Jennings LK, Murphy SA, et al. Association between platelet receptor occupancy after eptifibatide (integrilin) therapy and patency, myocardial perfusion, and ST-segment resolution among patients with ST-segment-elevation myocardial infarction: An INTEGRITI (Integrilin and Tenecteplase in Acute Myocardial Infarction) substudy. Circulation 2004;110:679-684.
33. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
34. Vallurupalli NG, Goldhaber SZ. Gastrointestinal complications of dual antiplatelet therapy. Circulation 2006;113:e655-e658.
35. Kastrati A, Mehilli J, Schlotterbeck K, et al. Early administration of reteplase plus abcix-imab vs abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention: A randomized controlled trial. JAMA 2004;291:947-954.
36. Sinnaeve PR, Huang Y, Bogaerts K, et al. Age, outcomes, and treatment effects of fibri-nolytic and antithrombotic combinations: Findings from Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT)-3 and ASSENT-3 PLUS. Am Heart J 2006;152:684,e681-e689.
37. Gunn J, Cumberland DC. Has stenting killed local drug delivery? Eur Heart J 1998;19:689-692.
38. Marciniak SJ Jr, Mascelli MA, Furman MI, et al. An additional mechanism of action of abciximab: Dispersal of newly formed platelet aggregates. Thromb Haemost 2002;87:1020-1025.
39. Collet J P, Montalescot G, Lesty C, et al. Effects of Abciximab on the architecture of platelet-rich clots in patients with acute myocardial infarction undergoing primary coronary intervention. Circulation 2001;103:2328-2331.
40. Hantgan RR, Mousa SA. Inhibition of platelet-mediated clot retraction by integrin antagonists. Thromb Res 1998;89:271-279.
41. Reverter JC, Beguin S, Kessels H, et al. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis." J Clin Invest 1996;98:863-874.
42. Cohen I, Burk DL, White JG. The effect of peptides and monoclonal antibodies that bind to platelet glycoprotein IIb-IIIa complex on the development of clot tension. Blood 1989;73:1880-1887.
43. Romagnoli E, Burzotta F, Trani C, et al. Rationale for intracoronary administration of abciximab. J Thromb Thrombolysis 2007;23:57-63.
44. Barsness G W, Buller C, Ohman EM, et al. Reduced thrombus burden with abciximab delivered locally before percutaneous intervention in saphenous vein grafts. Am Heart J 2000;139:824-829.
45. Bailey SR, O'Leary E, Chilton R. Angioscopic evaluation of site-specific administration of ReoPro. Cathet Cardiovasc Diagn 1997;42:181-184.
46. Kakkar AK, Moustapha A, Hanley HG, et al. Comparison of intracoronary vs. intravenous administration of abciximab in coronary stenting. Catheter Cardiovasc Interv 2004;61:31-34.
47. Bellandi F, Maioli M, Gallopin M, et al. Increase of myocardial salvage and left ventricular function recovery with intracoronary abciximab downstream of the coronary occlusion in patients with acute myocardial infarction treated with primary coronary intervention. Catheter Cardiovasc Interv 02004;62:186-192.
48. Galache Osuna JG, Sanchez-Rubio J, Calvo I,et al. Does intracoronary abciximab improve the outcome of percutaneous coronary interventions? A randomized controlled trial]. Rev Esp Cardiol 2006;59:567-574.
49. Romagnoli E, Burzotta F, Trani C, et al. Angiographic evaluation of the effect of intra-coronary abciximab administration in patients undergoing urgent PCI. Int J Cardiol 2005;105:250-255.
50. Thiele H, Schindler K, Friedenberger J, et al. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: The randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial. Circulation 2008;118:49-57.
51. Pinto DS, Kirtane AJ, Ruocco NA, et al. Administration of intracoronary eptifibatide during ST-elevation myocardial infarction. Am J Cardiol 2005;96:1494-1497.
52. Deibele AJ, Kirtane AJ, Pinto DS, et al. Intracoronary bolus administration of eptifibatide during percutaneous coronary stenting for non ST elevation myocardial infarction and unstable angina. J Thromb Thrombolysis 2006;22:47-50.
53. Yang XC, Zhang D P, Wang L F, et al. Effects of intracoronary or intravenous tirofiban administration in patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Zhonghua Xin Xue Guan Bing Za Zhi 2007;35:517-522.
54. Sharma S, Makkar R, Lardizabal J. Intracoronary administration of abciximab during percutaneous coronary interventions: Should this be the routine and preferred approach? J Cardiovasc Pharmacol Ther 2006;11:136-141.
55. Gunn J. Intra-coronary alteplase for extensive coronary artery thrombus. Heart 2007;93:1262.
56. Schieman G, Cohen BM, Kozina J, et al. Intracoronary urokinase for intracoronary thrombus accumulation complicating percutaneous transluminal coronary angioplasty in acute ischemic syndromes. Circulation 1990;82:2052-2060.
57. Mitchel J F, Azrin MA, Fram DB, et al. Inhibition of platelet deposition and lysis of in-tracoronary thrombus during balloon angioplasty using urokinase-coated hydrogel balloons. Circulation 1994;90:1979-1988.
58. Sezer M, Oflaz H, Goren T, et al. Intracoronary streptokinase after primary percutaneous coronary intervention. N Engl J Med 2007;356:1823-1834.
59. Woo KS, Armiger LC, White HD, Norris RM. Can streptokinase produce beneficial effects additional to coronary recanalization? Quantitative microvascular analysis of critically injured reperfused myocardium. Microvasc Res 2000;60:8-20.